Pharsight

Miebo patents expiration

MIEBO Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10058615 BAUSCH AND LOMB INC Semifluorinated alkane compositions
Sep, 2033

(9 years from now)

US10369117 BAUSCH AND LOMB INC Compositions comprising mixtures of semifluorinated alkanes
Sep, 2033

(9 years from now)

US10449164 BAUSCH AND LOMB INC Methods of treating ocular disorders using semifluorinated alkanes
Sep, 2033

(9 years from now)

US10576154 BAUSCH AND LOMB INC Semifluorinated alkane compositions
Sep, 2033

(9 years from now)

US11357738 BAUSCH AND LOMB INC Semifluorinated compounds and their compositions
Sep, 2036

(13 years from now)

US10507132 BAUSCH AND LOMB INC Topical administration method
Jun, 2037

(13 years from now)

Miebo is owned by Bausch And Lomb Inc.

Miebo contains Perfluorohexyloctane.

Miebo has a total of 6 drug patents out of which 0 drug patents have expired.

Miebo was authorised for market use on 18 May, 2023.

Miebo is available in solution/drops;ophthalmic dosage forms.

Miebo can be used as treatment of the signs and symptoms of dry eye disease (ded).

Drug patent challenges can be filed against Miebo from 2027-05-19.

The generics of Miebo are possible to be released after 21 June, 2037.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 18, 2028

Drugs and Companies using PERFLUOROHEXYLOCTANE ingredient

NCE-1 date: 2027-05-19

Market Authorisation Date: 18 May, 2023

Treatment: Treatment of the signs and symptoms of dry eye disease (ded)

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage

MIEBO family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic